Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B4TT
|
||||
| Former ID |
DCL000399
|
||||
| Drug Name |
GSK1004723
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] | Discontinued in Phase 1 | [1] | ||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C39H49ClN4O2
|
||||
| Canonical SMILES |
C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCCC3CN4C(=O)C5=CC=CC<br />=C5C(=N4)CC6=CC=C(C=C6)Cl
|
||||
| InChI |
1S/C39H49ClN4O2/c40-33-19-15-32(16-20-33)29-38-36-13-3-4-14-37(36)39(45)44(41-38)30-34-12-9-27-43(34)26-8-5-11-31-17-21-35(22-18-31)46-28-10-25-42-23-6-1-2-7-24-42/h3-4,13-22,34H,1-2,5-12,23-30H2/t34-/m0/s1
|
||||
| InChIKey |
YANGEESWIGIKOP-UMSFTDKQSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [2] | |
| Histamine H1 receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling eventsR-HSA-390650:Histamine receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028155) | ||||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.